Document is current

Article History

Received: 20 July 2023

Accepted: 12 March 2024

First Online: 5 April 2024

Declarations

:

: Formal ethics approval and informed consent from the 548 included patients were not required owing to the retrospective nature of this study and the anonymity of the study data. The study was conducted in accordance with all applicable national and international guidelines.

: Not applicable.

: Bertrand Mennecier declares participating in advisory boards, performing activities of consulting and clinical research, and attending conferences and speaking engagements organized by Roche, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Novartis, Takeda, Pfizer, Sanofi, Chugai, MSD, and Eli Lilly. Jonathan Khalifa declares participating in advisory boards, and receiving grants or honoraria from AstraZeneca, MSD, Bristol Myers Squibb, and Amgen. Renaud Descourt declares participating in advisory boards and attending conferences organized by Roche, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Novartis, Takeda, Pfizer, and Eli Lilly. Laurent Greillier declares receiving honoraria and travel/accommodation expenses, and performing activities of consulting for AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, MSD, Takeda, AbbVie, Novartis, and Pfizer. Charles Naltet reports receiving personal fees and/or non-financial support from AstraZeneca, MSD, Roche, Amgen, Bristol Myers Squibb, Takeda, and Pfizer. Lionel Falchero declares participating in advisory boards, performing activities of consulting and clinical research, receiving travel/accommodation expenses, and attending conferences and speaking engagements organized by Roche, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Sanofi, MSD, Menarini, GSK, Janssen-Cilag, and Amgen.